PT  - JOURNAL ARTICLE
AU  - Sebastian Weigang
AU  - Jonas Fuchs
AU  - Gert Zimmer
AU  - Daniel Schnepf
AU  - Lisa Kern
AU  - Julius Beer
AU  - Hendrik Luxenburger
AU  - Jakob Ankerhold
AU  - Valeria Falcone
AU  - Janine Kemming
AU  - Maike Hofmann
AU  - Robert Thimme
AU  - Christoph Neumann-Haefelin
AU  - Svenja Ulferts
AU  - Robert Grosse
AU  - Daniel Hornuss
AU  - Yakup Tanriver
AU  - Siegbert Rieg
AU  - Dirk Wagner
AU  - Daniela Huzly
AU  - Martin Schwemmle
AU  - Marcus Panning
AU  - Georg Kochs
TI  - Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient: a source of immune escape variants
AID  - 10.1101/2021.04.30.21256244
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.30.21256244
4099  - http://medrxiv.org/content/early/2021/05/05/2021.04.30.21256244.short
4100  - http://medrxiv.org/content/early/2021/05/05/2021.04.30.21256244.full
AB  - The recent emergence of SARS-CoV-2 variants showing increased transmissibility and immune escape is a matter of global concern. Their origin remains unclear, but intra-host virus evolution during persistent infections could be a contributing factor. Here, we studied the long-term SARS-CoV-2 infection in an immunosuppressed organ transplant recipient. Frequent respiratory specimens were tested for variant viral genomes by RT-qPCR, next-generation sequencing (NGS), and virus isolation. Late in infection, several virus variants emerged which escaped neutralization by COVID-19 convalescent and vaccine-induced antisera and had acquired genome mutations similar to those found in variants of concern first identified in UK, South Africa, and Brazil. Importantly, infection of susceptible hACE2-transgenic mice with one of the patient’s escape variants elicited protective immunity against re-infection with either the parental virus, the escape variant or the South African variant of concern, demonstrating broad immune control. Upon lowering immunosuppressive treatment, the patient generated spike-specific neutralizing antibodies and resolved the infection. Our results indicate that immunocompromised patients are an alarming source of potentially harmful SARS-CoV-2 variants and open up new avenues for the updating of COVID-19 vaccines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Bundesministerium fuer Bildung und Forschung (BMBF) through the Deutsches Zentrum fuer Luft- und Raumfahrt, Germany, (DLR, grant number 01KI2077) to MP, RT and MS and by the Federal State of Baden-Wuerttemberg, Germany, MWK-Sonderfoerdermassnahme COVID-19/AZ.:33-7533.-6-21/7/2 to MS and AZ33-7533-6-10/89/8 to CNH. The funders had no role in the study design, data analysis, data interpretation, and in the writing of this report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project has been approved by the University Medical Center, Freiburg, ethical committee. Written informed consent was obtained from all participants and the study was conducted according to federal guidelines, local ethics committee regulations (Albert-Ludwigs-Universitaet, Freiburg, Germany: No. F-2020-09-03-160428 and no. 322/20) and the Declaration of Helsinki (1975). All routine virological laboratory testing of patient specimens was performed in the Diagnostic Department of the Institute of Virology, University Medical Center, Freiburg (Local ethics committee no. 1001913).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll necessary data and informations are given in the manuscript. The sequence data are submitted to GISAID data base and are publicly available (Extended data table 2). Further additional informations about the patient will not be shared due to protection of individual privacy. https://github.com/jonas-fuchs/SARS-CoV-2-analyses